system: You are a contract-analysis assistant performing a span-extraction task. You are given an excerpt from a commercial contract and the name of a clause type to locate within it.

Return the exact text of the requested clause, copied verbatim from the excerpt — identical wording and punctuation, with no paraphrasing, summarising, explanation, or added commentary.

The excerpt is one window of a much longer contract and often will not contain the requested clause. If the requested clause does not appear in this excerpt, respond with exactly: Not found.

Output only the extracted clause text, or the exact string `Not found.` — nothing else.

user: Contract excerpt:
"""
Exhibit 10.1 [*] Certain confidential information contained in this document, marked by brackets, is omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (this "Agreement") is made this, 20t h day of January, 2020 (the "Effective Date"), by and between HOVIONE INTER AG, together with its subsidiaries and affiliates, and organized and existing under the laws of Switzerland and having its registered office at Pilatusstrasse 23, CH-6003, Luzern, Switzerland (hereafter referred to as "HOVIONE"), and INTERSECT ENT, Inc. together with its subsidiaries and affiliates, and organized and existing under the laws of Delaware and having its registered office at 1555 Adams Drive, Menlo Park, CA 94025 (hereafter referred to as "INTERSECT"). HOVIONE and INTERSECT are each sometimes referred to herein as a "Party" and together as the "Parties." WHEREAS, HOVIONE has developed and manufacturers the active pharmaceutical ingredient(s) identified in Exhibit A hereto (the "API"); and WHEREAS, INTERSECT develops and markets Finished Product based on the API, as defined herein; and WHEREAS, INTERSECT desires to acquire API from HOVIONE to incorporate into the Finished Product; and WHEREAS, HOVIONE is willing to supply such API for INTERSECT's use, on the terms and conditions set forth in this Agreement. NOW THEREFORE, in consideration of the promises and the mutual covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree and covenant as follows: 1. Definitions 1.1. "Active Pharmaceutical Ingredient" or "API" shall have the meaning given such term in the preamble hereof. 1.2. "Affiliate" means any entity controlling, controlled by or under common control with either Party hereto. For purpose of this definition, "control" shall mean ownership of over fifty percent (50%) of the equity capital, the outstanding voting securities or other ownership interest of an entity, or the right to receive over fifty percent (50%) of the profits or earnings of an entity. In the case of non-stock organizations, the term "control" shall mean the power to control the distribution of profits. 1.3. "Applicable Law" shall mean the laws, regulations, rules and guidelines pertaining to the development, manufacture, packaging, labeling, storage, import, export, distribution, marketing, sale and/or intended use of the API or the Finished Product. 1.4. "Batch Record" shall mean a batch manufacturing record, prepared according to applicable cGMP guidelines, for every production batch of API. 1.5. "Confidential Information" shall mean all the technical information, whether tangible or intangible, including (without limitation) any and all data, techniques, discoveries, inventions, processes, know-how, patent applications, inventor certificates, trade secrets, methods of production and other proprietary information, that either Party or its Affiliates have ownership rights to (as either owner, licensee or sub-licensee), or may hereafter obtain rights. 1 1.6. "Current Good Manufacturing Practices" or "cGMP" shall mean current Good Manufacturing Practice as set forth by the US FDA as well as current good manufacturing practices applicable to the API, or the making thereof at HOVIONE's manufacturing facility, set forth by the relevant Regulatory Agency. 1.7. "Defect" with respect to the API shall mean failure of the API to comply with the Product Specifications. 1.8. "FDA shall mean the US Food and Drug Administration, and any successor thereto. 1.9. "Finished Product" shall mean the finished dosage form combination drug and device product that contains the API ready for clinical use or commercial sale. 1.10. "Firm Forecast" shall have the meaning given to such term in Section 3.2 hereof. 1.11. "Product Specifications" shall have the meaning given to such term in Section 2.2 hereof. 1.12. "Quality Agreement" shall mean that certain Quality Assurance Agreement, dated of even date herewith, by and between INTERSECT and HOVIONE, which sets forth (a) the roles and responsibilities of the Parties with respect to the quality assurance for the API and (b) how the Parties' quality operations shall interact with each other in connection with the same. 1.13. "Regulatory Agency" shall mean national, or other government entities regulating or otherwise exercising authority with respect to the API or the Finished Product in the United States including, without limitation, the US FDA 1.14. "Term" shall have the meaning assigned to such term in Section 10. 2. Manufacture and Sale 2.1. Supply. During the term of this Agreement and subject to the terms and conditions set forth herein, INTERSECT shall purchase [*] of its annual API requirement, from HOVIONE and HOVIONE shall manufacture and supply API to INTERSECT (or a third party designated by
"""

Extract the exact clause related to "Effective Date" from the excerpt above.

assistant: 20t h day of January, 2020